TARGETING CD47 WITH Fc-ENHANCED ACTIVITY
AssigneeThe Rockefeller University
InventorsJeffrey V. Ravetch, Juan Osorio
Life of this patent
Estimating the term…
Abstract
This disclosure provides anti-CD47 antibodies or antigen-binding portions thereof comprising a modified Fc region that activates FcγRs and enhances in vivo antitumor activity. This disclosure further provides a humanized CD47/SIRPα/FcγR mouse model for evaluating anti-CD47 antibodies or antigen-binding portions thereof.
Claims25
An isolated antibody or antigen-binding portion thereof that specifically binds to human CD47, wherein the antitumor activity of the antibody or antigen-binding portion thereof comprises an Fc region modified to enhance the antitumor activity of the antibody or antigen-binding portion thereof, and wherein the Fc region comprises at least one mutation that is G236A/A330L/1332E with respect to SEQ ID NO:
- 13.
A mouse model for evaluating an anti-CD47 antibody or antigen-binding portion thereof, wherein the mouse comprises a humanized CD47, a humanized SIRPα, and humanized FcγRs.
A method of boosting systemic antitumor immunity with minimal toxicity, comprising intratumorally administering to a subject in need thereof a therapeutically effective amount of an isolated antibody or antigen-binding portion thereof that specifically binds to human CD47, wherein the antibody or antigen-binding portion thereof comprises an Fc region modified to enhance the antitumor activity of the antibody or antigen-binding portion thereof, and wherein the Fc region comprises at least one mutation that is G236A/A330L/1332E with respect to SEQ ID NO:
- 13.
Dependencies are inferred from the claim text.